Antiplatelet and Antithrombotic Properties of Compound L-36, a 6H-1,3,4-Thiadiazine Derivative.
Bull Exp Biol Med
; 177(1): 63-67, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38954300
ABSTRACT
Compound L-36, a new derivative of 6H-1,3,4-thiadiazine, was studied in in vitro and in vivo experiments. This compound exhibits high antiplatelet and antithrombogenic activity. In in vitro experiments, compound L-36 by its antiplatelet activity (by IC50) was superior to acetylsalicylic acid by 9.4 times. In in vivo experiments, compound L-36 by its ED50 value was close to the comparison drug. On the model of pulmonary artery thrombosis, compound L-36 ensured better survival of experimental animals than acetylsalicylic acid. Morphological studies showed that compound L-36 effectively attenuated the thrombosis processes in the pulmonary tissue induced by intravenous injection of a thrombogenic mixture (epinephrine and collagen).
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Tiadiazinas
/
Inhibidores de Agregación Plaquetaria
/
Agregación Plaquetaria
/
Aspirina
/
Fibrinolíticos
Límite:
Animals
Idioma:
En
Revista:
Bull Exp Biol Med
/
Bull. exp. biol. med
/
Bulletin of experimental biology and medicine
Año:
2024
Tipo del documento:
Article
País de afiliación:
Rusia